Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Tri-I TDI gains AlivaMab Mouse license
February 2017
SHARING OPTIONS:

BURLINGAME, Calif.—Ablexis LLC and the Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI) have struck up a non-exclusive, perpetual license agreement for access to the AlivaMab Mouse for antibody drug discovery and development. With this deal, the Tri-I TDI gains its own colony of AlivaMab Mouse and broad rights to use it for antibody drug discovery and development. The Tri-I TDI is an initiative by Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine that discovers small molecules and biologics for proof-of-concept studies. Financial details were not disclosed.
 
“This agreement with Ablexis opens up new opportunities for innovation in our community,” said Tri-I TDI CEO Dr. Michael Foley. “We are delighted that the AlivaMab Mouse platform can now be applied to the breakthrough scientific findings of our investigators to discover new drugs. This has the potential to accelerate the rate with which we can bring new therapies to patients.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.